296275-13-3

Upstream product

• 134-20-3 2-carbomethoxyaniline 
• 98-74-8 4-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1153132-83-2 2-(4-amino-benzenesulfonylamino)-benzoic acid methyl ester 
• 38957-45-8 2-(4-nitro-benzenesulfonylamino)benzoic acid 
• 1446489-48-0 N-(2,4-dichlorophenyl)-2-(4-nitrophenylsulfonamido)benzamide 
• 1446489-50-4 N-(3-chloro-4-fluorophenyl)-2-(4-nitrophenylsulfonamido)benzamide 
• 1454274-90-8 N-(4-methyl-3-(trifluoromethyl)phenyl)-2-(4-nitrophenylsulfonamido)benzamide 
• 1446489-51-5 N-(3-(difluoromethoxy)phenyl)-2-(4-nitrophenylsulfonamido)benzamide 
• 1446489-52-6 2-(4-nitrophenylsulfonamido)-N-(3-(trifluoromethoxy)phenyl)benzamide 
• 1446489-53-7 N-(3,4-dichlorophenyl)-2-(4-nitrophenylsulfonamido)benzamide 

Relevant academic research and scientific papers

Arylsulfonylamino-benzanilides as inhibitors of the apical sodium-dependent bile salt transporter (SLC10A2)

The apical sodium-dependent bile salt transporter (ASBT) plays a pivotal role in maintaining bile acid homeostasis. Inhibition of ASBT would reduce bile acid pool size and lower cholesterol levels. In this report, a series of novel arylsulfonylaminobenzan

ORGANIC COMPOUNDS

Compounds of the formula (I) provide pharmacological agents which bind to Peroxisome Proliferator-Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compounds of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X.